Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Prostate Cancer

Clinical Trial at: Texas Oncology - Allen

Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)

  • Details

ClinicalTrials.gov ID: NCT03871816
Diagnosis Type: NA
USOR Number: 19144

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Allen

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Details

ClinicalTrials.gov ID: NCT04083976
Diagnosis Type: NA
USOR Number: 19092

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Allen

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Details

ClinicalTrials.gov ID: NCT04083976
Diagnosis Type: NA
USOR Number: 19092

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

(MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

  • Details

ClinicalTrials.gov ID: NCT03817853
Diagnosis Type: NA
USOR Number: 18265

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

(MO40597) A MULTICENTRIC, OPEN-LABEL, SINGLE ARM STUDY OF OBINUTUZUMAB SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA (PHASE IV STUDY)

  • Details

ClinicalTrials.gov ID: NCT03817853
Diagnosis Type: NA
USOR Number: 18265

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Allen

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Allen

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Allen

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Allen

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Texas Oncology - Allen

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Texas Oncology - Allen

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Allen

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: NA
USOR Number: 19079

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Allen

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: NA
USOR Number: 19079

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: NA
USOR Number: 19018

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Allen

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number: 19020

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Allen

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205)

  • Details

ClinicalTrials.gov ID: NCT02793583
Diagnosis Type: Non-Hodgkins
USOR Number: 16065

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Allen

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

  • Details

ClinicalTrials.gov ID: NCT03053193
Diagnosis Type: NA
USOR Number: 17079

  • Practice Details

1105 Central Expressway, Suite 320
Allen, Texas 75013
279.71 mi. away
P: (469) 467-4392

More Details View Practice Page

Pages